Results 131 to 140 of about 89,048 (269)

The different face of skin‐rash induced by brentuximab vedotin

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background: Brentuximab vedotin (BV) is a targeted therapy for CD30‐expressing lymphomas, including Hodgkin lymphoma (HL) and cutaneous T‐cell lymphoma (CTCL). While peripheral neuropathy is the most common adverse event, BV‐induced skin rashes are less frequent and not well characterized.
Alessandro Pileri, Tullio Brunetti, Serena Rupoli, Gianluca Cafasso, Corrado Zengarini, Staphano Cedirian, Federico Bardazzi, Cosimo Misciali, Michela Starace, Claudio Agostinelli, Gaia Goteri, Erika Morsia   +11 more
wiley   +1 more source

Downregulation of O‐GlcNAcylation enhances etoposide‐induced p53‐mediated apoptosis in HepG2 human liver cancer cells

FEBS Open Bio
Etoposide, an anticancer drug that inhibits topoisomerase II, is commonly used in combination chemotherapy. However, the impact of O‐GlcNAcylation regulation on etoposide's anticancer effects has rarely been investigated.
Jaehoon Lee, Gi‐Bang Koo, Jihye Park, Byung‐Cheol Han, Mijin Kwon, Seung‐Ho Lee   +5 more
doaj   +1 more source

Post‐Transplant Bendamustine as a Platform for Immune Modulation After Allogeneic Hematopoietic Cell Transplantation

European Journal of Haematology, EarlyView.
ABSTRACT Post‐transplant cyclophosphamide (PT‐CY) remains the standard of care for graft‐versus‐host disease (GvHD) prophylaxis in haploidentical hematopoietic cell transplantation (HCT), yet relapse, delayed immune reconstitution, infections, and organ toxicity represent persistent and clinically meaningful limitations.
Megan J. Cracchiolo, Richard J. Simpson, Emmanuel Katsanis   +2 more
wiley   +1 more source

Survival After Diagnosis of Cardiovascular Disease in Survivors of Adolescent and Young Adult Lymphoma

European Journal of Haematology, EarlyView.
ABSTRACT Cardiac dysfunction is a major morbidity among survivors of adolescent and young adult (AYA) lymphoma. Although high mortality after cardiovascular disease (CVD) diagnosis has been shown in other cancer survivor populations, this has not been investigated in a diverse population of survivors of AYA lymphoma.
Karan Gowda, Medha Gupta, Adrian Aguilar, Carlos Cruz, Amanda Warner, Elizabeth R. Rodriguez, Sairah Ahmed, Branko Cuglievan, Joel Milam, David R. Freyer, Kimberly A. Miller, Greg Aune, Debra Eshelman‐Kent, Karen Albritton, Efstratios Koutroumpakis, Michael E. Roth, Jian Wang, Michelle A. T. Hildebrandt   +17 more
wiley   +1 more source

Etoposide [PDF]

Reactions Weekly, 2020
  +4 more sources

A Case of Small Cell Carcinoma of Bladder With Significant Tumor Reduction Following Combination Chemotherapy and Radiation Therapy

IJU Case Reports
Introduction Small cell carcinoma of the bladder (SCCB) is a rare and aggressive disease with no established standard treatment. We report a case of SCCB that initially progressed with chemotherapy but responded well to a combination of chemotherapy and ...
Rintaro Yoshitake, Syunsuke Taguchi, Yoshimasa Harada   +2 more
doaj   +1 more source

KU80 suppresses endonuclease G activity to preserve genomic integrity

The FEBS Journal, EarlyView.
Under normal conditions, EndoG remains restricted to mitochondria and the genome remains intact. When KU80 is absent, EndoG translocates into the nucleus, where it promotes DNA fragmentation and genomic instability. Thus, this work highlights the importance of KU80 in tightly controlling EndoG localization to preserve genome stability.
Jargalan Batsaikhan, Kwang‐Hyun Park, Hae Ryung Chang, Eunyoung Jung, Myung‐Jin Kim, Jeeyoon Kang, Hyunjo Shim, Eui‐Jeon Woo, Yonghwan Kim   +8 more
wiley   +1 more source

Medication Safety in Intravenous Therapy: Compatibility of Etoposide With Frequently Drugs Used in Tumour Critical Care During Simulated Y-Site Administration [Corrigendum]

Drug Design, Development and Therapy
Ding H, Tong T, Liu S, Tang L, Chen Z. Drug Des Devel Ther. 2025;19:1147—1161. The authors have advised there is an error in Figure 1 on page 1151. The text “Particles > 25 µm≤25 particles/mL” should read &
Ding H, Tong T, Liu S, Tang L, Chen Z
doaj  

Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease

Internal Medicine Journal, EarlyView.
Abstract Idiopathic multicentric Castleman disease (iMCD) is a rare condition. The pathogenesis is incompletely understood; however, interleukin‐6 (IL‐6) is a major mediator. The clinical presentation is heterogeneous, from mild constitutional symptoms to severe multi‐organ failure.
Dipti Talaulikar, Jun Yen Ng, Adam Bryant, Annmarie Bosco, Hugh C. Caterson, Pratyush Giri, Pravin Hissaria, Simon J. Harrison, Stephen Lade, Connull Leslie, Jacinta Perram, H. Miles Prince, Dejan Radeski, Maureen Rischmueller, Craig Wallington‐Gates, Nicholas Weber, Alberta Hoi   +16 more
wiley   +1 more source

PHARMACOKINETIC STUDY OF INTRAPERITONEALLY ADMINISTERED ETOPOSIDE AGAINST PERITONITIS CARCINOMATOSA [PDF]

, 1994
Etoposide is becoming important in primary and salvage therapy for ovarian cancer. In the present study, we administered etoposide (100-300 mg/subject) intraperitoneally to six patients suffering from cancerous peritonitis, particularly that resulting ...
Noda, Tsuneo, Kiyozuka, Yasuhiko, Ito, Kimihiko, Itani, Yoshio, Adachi, Susumu   +4 more
core